Clinical impact of using [
[18F]AlF‐NOTA‐octreotide
[68Ga]Ga‐DOTA‐TATE
clinical management
neuroendocrine tumor
somatostatin receptor
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
revised:
06
05
2024
received:
05
02
2024
accepted:
21
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
[
Banques de données
ClinicalTrials.gov
['NCT04552847']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13420Informations de copyright
© 2024 British Society for Neuroendocrinology.
Références
Pauwels E, Cleeren F, Tshibangu T, et al. 18F‐AlF‐NOTA‐octreotide outperforms 68Ga‐DOTA‐TATE/‐NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2023;64:632‐638.
Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population‐based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589‐597.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga‐DOTA‐conjugated somatostatin receptor targeting peptides and 18F‐DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588‐1601.
Deroose CM, Hindié E, Kebebew E, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949‐1956.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59:66‐74.
Pauwels E, Cleeren F, Bormans G, Deroose MC. Somatostatin receptor PET ligands—the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311‐331.
Leupe H, Ahenkorah S, Dekervel J, et al. 18F‐labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. 2023;64:835‐841.
Tshibangu T, Cawthorne C, Serdons K, et al. Automated GMP compliant production of [18F]AlF‐NOTA‐octreotide. EJNMMI Radiopharm Chem. 2020;5:1‐23.
Pauwels E, Cleeren F, Tshibangu T, et al. Al18F‐NOTA‐octreotide: first comparison with 68Ga‐DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging. 2019;46:2398‐2399.
Pauwels E, Cleeren F, Tshibangu T, et al. [18F]AlF‐NOTA‐octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga‐DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47:3033‐3046.
Hou J, Long T, He Z, et al. Evaluation of 18F AlF NOTA octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga‐DOTATATE PET/CT. EJNMMI Res. 2021;11:55.
Haeger A, Soza‐Ried C, Kramer V, et al. Al[18F]F‐NOTA‐octreotide is comparable to [68Ga]Ga‐DOTA‐TATE for PET/CT imaging of neuroendocrine tumours in the Latin‐American population. Cancers (Basel). 2023;15:1‐11.
Brierley J, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Wiley‐Blackwell; 2016.
Amin M, Edge S, Greene F, Byrd D, Brookland R. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2018.
Pavel M, De Herder WW. ENETS consensus guidelines for the standards of care in neuroendocrine tumors. Neuroendocrinology. 2017;105:193‐195.
Boeckxstaens L, Pauwels E, Vandecaveye V, et al. Prospective comparison of [18F]AlF‐NOTA‐octreotide PET/MRI to [68Ga]Ga‐DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res. 2023;13:1‐13.
Long T, Yang N, Zhou M, et al. Clinical application of 18F‐AlF‐NOTA‐octreotide PET/CT in combination with 18F‐FDG PET/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44:452‐458.
Strosberg J, el‐Haddad G, Wolin E, et al. Phase 3 trial of 177Lu‐Dotatate for midgut neuroendocrine tumors. N Engl J Med [Internet]. 2017;376:125‐135.